Entrada Therapeutics TRDA
NASDAQ TRDA
$4.94 -0.05 (-0.96%)
As of: Oct 21, 2026 · 1:50 PM EDT

Entrada Therapeutics (TRDA) Total Non-Current Liabilities (2021 - 2022)

Updated

Entrada Therapeutics' Total Non-Current Liabilities was $39.88 million in Q2 2022, up 1.4% from the prior quarter.

Analysis

Entrada Therapeutics (TRDA) Total Non-Current Liabilities (2021 - 2022) Analysis & Trends

At the end of FY2021, Total Non-Current Liabilities at Entrada Therapeutics came in at $6.72 million.

  • Quarterly Total Non-Current Liabilities has moved between $6.72 million (Q4 2021) and $204.65 million (Q3 2021) over five years.
  • Per Business Quant data, TRDA's Total Non-Current Liabilities in the three quarters before Q2 2022 was $39.31 million (Q1 2022), $6.72 million (Q4 2021) and $204.65 million (Q3 2021).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Eli Lilly 1,134.24 Bn 1,102.83 Bn 19.71 Bn 60.66 Bn
2 Johnson & Johnson 616.05 Bn 534.58 Bn 17.26 Bn 105.50 Bn
3 AbbVie 500.90 Bn 474.01 Bn 12.70 Bn 106.45 Bn
4 Merck 367.17 Bn 321.54 Bn 12.21 Bn 80.25 Bn
5 Novartis Ag 297.85 Bn 261.84 Bn 11.24 Bn 48.34 Bn
6 Astrazeneca 261.35 Bn 235.03 Bn 12.86 Bn 33.91 Bn
7 Amgen 235.77 Bn 191.17 Bn 7.24 Bn 78.66 Bn
8 Gilead Sciences 190.70 Bn 164.90 Bn 6.22 Bn 35.10 Bn
9 Pfizer 169.35 Bn 115.99 Bn 10.94 Bn 97.04 Bn
10 Entrada Therapeutics 208.66 Mn -150.74 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2022 39.88 Mn
Mar 31, 2022 39.31 Mn
Dec 31, 2021 6.72 Mn
Sep 30, 2021 204.65 Mn
API Access

Entrada Therapeutics Total Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-non-current-liabilities&ticker=TRDA&period=max&api_key=YOUR_API_KEY